<DOC>
	<DOCNO>NCT00004198</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Vaccines may make body build immune response kill tumor cell . Sargramostim may stimulate person 's immune system help kill tumor cell . PURPOSE : Phase II trial study effectiveness vaccine therapy plus sargramostim follow chemotherapy treat patient stage III stage IV non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Vaccine Therapy Plus Sargramostim Following Chemotherapy Treating Patients With Stage III Stage IV Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine ability recombinant idiotype immunotherapy stimulate specific immune response B cell idiotype malignant clone constitutes tumor patient previously untreated stage III IV indolent non-Hodgkin 's lymphoma . II . Determine safety toxicity treatment regimen use Genitope Corporation 's molecular rescue technology patient population . OUTLINE : Patients receive induction chemotherapy consist oral cyclophosphamide , vincristine , prednisone ( CVP ) . Treatment repeat every 3 week maximal clinical response achieve follow 2 additional course consolidation therapy maximum 10 course . Patients achieve adequate response receive 6 course alternate chemotherapy consist cyclophosphamide , doxorubicin , vincristine , prednisone . At 3 month 1 year follow completion chemotherapy , patient achieve adequate disease response receive vaccination consist recombinant tumor derive immunoglobulin idiotype keyhole limpet hemocyanin conjugate subcutaneously ( SQ ) 2 site immediately follow sargramostim ( GM-CSF ) SQ day 1 . Patients receive GM-CSF alone day 2-4 . Vaccination repeat every 4 week 4 dos , follow 12 week later fifth final dose . Patients follow every 3 month 2 year , every 6 month 2 year , annually thereafter disease progression . PROJECTED ACCRUAL : Not specify</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Keyhole-limpet hemocyanin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm stage III IV , indolent nonHodgkin 's lymphoma Follicular small cleave cell Follicular mix small cleave large cell le 50 % large cell No intermediate , high grade , nonHodgkin 's lymphoma ( e.g. , mantle cell , monocytoid B cell , marginal zone , small lymphocytic , chronic lymphocytic leukemia , follicular large cell ) Tumor sample safely accessible biopsy , needle aspiration , phlebotomy Must adequate circulate lymphoma cell No CNS metastasis A new classification scheme adult nonHodgkin 's lymphoma adopt PDQ . The terminology `` indolent '' `` aggressive '' lymphoma replace former terminology `` low '' , `` intermediate '' , `` high '' grade lymphoma . However , protocol us former terminology . PATIENT CHARACTERISTICS : Age : Over 18 Performance status : Karnofsky 80100 % Life expectancy : Not specify Hematopoietic : WBC great 2,500/mm3 Platelet count great 100,000/mm3 Hemoglobin least 10 g/dL Hepatic : Bilirubin le 2 mg/dL SGOT/SGPT le 2 time normal Renal : Creatinine le 2 mg/dL Other : No illness condition , include innate pharmacologic immunosuppression , would preclude study No malignancy within last 5 year except adequately treat basal squamous cell skin cancer carcinoma situ cervix HIV negative Not pregnant nurse PRIOR CONCURRENT THERAPY : Biologic : No prior biologic therapy lymphoma Chemotherapy : No prior cytotoxic therapy lymphoma Endocrine : No prior steroid lymphoma At least 2 month since prior nonphysiologic dos prednisone great 20 mg equivalent No concurrent maintenance steroid great 5 mg daily prednisone equivalent Radiotherapy : No prior radiotherapy lymphoma Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
</DOC>